EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 490-499 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 490 - 499
Section La psychiatrie de précision (PEPR PROPSY) : premiers succès
DOI https://doi.org/10.1051/medsci/2025063
Published online 26 May 2025
  1. Chan JKN, Correll CU, Wong CSM, et al. Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis. EClinicalMedicine 2023 ; 65 : 102294. [CrossRef] [PubMed] [Google Scholar]
  2. Meng R, Yu C, Liu N, et al. Association of depression with all-cause and cardiovascular disease mortality among adults in China. JAMA Netw Open 2020 ; 3 : e1921043. [CrossRef] [PubMed] [Google Scholar]
  3. Lambert AM, Parretti HM, Pearce E, et al. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: a systematic review and meta-analysis. PLoS Med 2022 ; 19 : e1003960. [CrossRef] [PubMed] [Google Scholar]
  4. Coldefy M, Gandré C. Personnes suivies pour des troubles psychiques sévères : une espérance de vie fortement réduite et une mortalité prématurée quadruplée. Questions Économie Santé 2018 ; n° 237. [Google Scholar]
  5. Wu Q, Kling JM. Depression and the risk of myocardial infarction and coronary death: a meta-analysis of prospective cohort studies. Medicine (Baltimore) 2016 ; 95 : e2815. [CrossRef] [PubMed] [Google Scholar]
  6. Feng L, Li L, Liu W, et al. Prevalence of depression in myocardial infarction: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019 ; 98 : e14596. [CrossRef] [PubMed] [Google Scholar]
  7. Prieto ML, Cuéllar-Barboza AB, Bobo WV, et al. Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis. Acta Psychiatr Scand 2014 ; 130 : 342–53. [CrossRef] [PubMed] [Google Scholar]
  8. Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 2013 ; 47 : 1549–56. [CrossRef] [PubMed] [Google Scholar]
  9. Yu M, Zhang X, Lu F, et al. Depression and risk for diabetes: a meta-analysis. Can J Diabetes 2015 ; 39 : 266–72. [CrossRef] [PubMed] [Google Scholar]
  10. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016 ; 15 : 166–74. [CrossRef] [PubMed] [Google Scholar]
  11. Frank P, Batty GD, Pentti J, et al. Association between depression and physical conditions requiring hospitalization. JAMA Psychiatry 2023 ; 80 : 690–9. [CrossRef] [PubMed] [Google Scholar]
  12. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015 ; 14 : 339–47. [CrossRef] [PubMed] [Google Scholar]
  13. Chieh AY, Bryant BM, Kim JW, et al. Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction. Res Autism Spectr Disord 2021 ; 86 : 101821. [CrossRef] [PubMed] [Google Scholar]
  14. Li YJ, Xie XN, Lei X, et al. Global prevalence of obesity, overweight and underweight in children, adolescents and adults with autism spectrum disorder, attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Obes Rev 2020 ; 21 : e13123. [CrossRef] [PubMed] [Google Scholar]
  15. Godin O, Etain B, Henry C, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry 2014 ; 75 : 1078–85. [CrossRef] [PubMed] [Google Scholar]
  16. Godin O, Bennabi D, Yrondi A, et al. Prevalence of metabolic syndrome and associated factors in a cohort of individuals with treatment-resistant depression: results from the FACE-DR study. J Clin Psychiatry 2019 ; 80 : 19m12755. [CrossRef] [PubMed] [Google Scholar]
  17. Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol 2021 ; 12 : 769309. [CrossRef] [PubMed] [Google Scholar]
  18. Lamers F, Milaneschi Y, Vinkers CH, et al. Depression profilers and immuno-metabolic dysregulation: longitudinal results from the NESDA study. Brain Behav Immun 2020 ; 88 : 174–83. [CrossRef] [PubMed] [Google Scholar]
  19. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev 2015 ; 52 : 89–104. [CrossRef] [PubMed] [Google Scholar]
  20. Vreijling SR, Chin Fatt CR, Williams LM, et al. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials. Br J Psychiatry J Ment Sci 2024 ; 224 : 89–97. [CrossRef] [PubMed] [Google Scholar]
  21. Penninx BWJH, Lamers F, Jansen R, et al. Immuno-metabolic depression: from concept to implementation. Lancet Reg Health Eur 2024 ; 48 : 101166. [Google Scholar]
  22. Zhao C, Habtewold TD, Naderi E, et al. Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders. Eur Psychiatry 2023 ; 67 : e7. [Google Scholar]
  23. Hagi K, Nosaka T, Dickinson D, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 2021 ; 78 : 510–8. [CrossRef] [PubMed] [Google Scholar]
  24. Perry BI, McIntosh G, Weich S, et al. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry 2016 ; 3 : 1049–58. [CrossRef] [PubMed] [Google Scholar]
  25. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020 ; 7 : 64–77. [CrossRef] [PubMed] [Google Scholar]
  26. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. Obes Rev 2019 ; 20 : 1680–90. [CrossRef] [PubMed] [Google Scholar]
  27. Amare AT, Schubert KO, Klingler-Hoffmann M, et al. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry 2017 ; 7 : e1007. [CrossRef] [PubMed] [Google Scholar]
  28. Gilgenkrantz H. La pléiotropie antagoniste et le paradoxe de la sénescence. Med Sci (Paris) 2025 ; 41 : 68. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  29. Malan-Müller S, Kilian S, Heuvel LL van den, et al. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophr Res 2016 ; 170 : 1–17. [CrossRef] [PubMed] [Google Scholar]
  30. Lu Y, Wang Z, Georgakis MK, et al. Genetic liability to depression and risk of coronary artery disease, myocardial infarction, and other cardiovascular outcomes. J Am Heart Assoc 2021 ; 10 : e017986. [CrossRef] [PubMed] [Google Scholar]
  31. Li Z, Chen P, Chen J, et al. Glucose and insulin-related traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study. EBioMedicine 2018 ; 34 : 182–8. [CrossRef] [PubMed] [Google Scholar]
  32. Meijsen J, Hu K, Krebs MD, et al. Quantifying the relative importance of genetics and environment on the comorbidity between mental and cardiometabolic disorders using 17 million Scandinavians. Nat Commun 2024 ; 15 : 5064. [CrossRef] [PubMed] [Google Scholar]
  33. Milaneschi Y, Lamers F, Peyrot WJ, et al. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. JAMA Psychiatry 2017 ; 74 : 1214–25. [CrossRef] [PubMed] [Google Scholar]
  34. Capuron L, Lasselin J, Castanon N. Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 2017 ; 42 : 115–28. [CrossRef] [PubMed] [Google Scholar]
  35. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012 ; 141 : 1–10. [CrossRef] [PubMed] [Google Scholar]
  36. Sankararaman S, Noriega K, Velayuthan S, et al. Gut microbiome and its impact on obesity and obesity-related disorders. Curr Gastroenterol Rep 2023 ; 25 : 31–44. [CrossRef] [PubMed] [Google Scholar]
  37. Lasselin J, Capuron L. Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. Neuroimmunomodulation 2014 ; 21 : 95–101. [CrossRef] [PubMed] [Google Scholar]
  38. Osimo EF, Baxter LJ, Lewis G, et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med 2019 ; 49 : 1958–70. [CrossRef] [PubMed] [Google Scholar]
  39. Selosse MA. Les mitochondries, organites ou bactéries ? Med Sci (Paris) 2024 ; 40 : 197–8. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  40. Giménez-Palomo A, Dodd S, Anmella G, et al. The Role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment. Front Psychiatry 2021 ; 12 : 546801. [CrossRef] [PubMed] [Google Scholar]
  41. Frye RE, Rincon N, McCarty PJ, et al. Biomarkers of mitochondrial dysfunction in autism spectrum disorder: a systematic review and meta-analysis. Neurobiol Dis 2024 ; 197 : 106520. [CrossRef] [PubMed] [Google Scholar]
  42. Zachos KA, Choi J, Godin O, et al. Mitochondrial biomarkers and metabolic syndrome in bipolar disorder. Psychiatry Res 2024 ; 339 : 116063. [CrossRef] [PubMed] [Google Scholar]
  43. Bernard J, Tamouza R, Godin O, et al. Mitochondria at the crossroad of dysregulated inflammatory and metabolic processes in bipolar disorders. Brain Behav Immun 2024 ; 123 : 456–65. [Google Scholar]
  44. Ozsoy S, Besirli A, Abdulrezzak U, et al. Serum ghrelin and leptin levels in patients with depression and the effects of treatment. Psychiatry Investig 2014 ; 11 : 167–72. [CrossRef] [PubMed] [Google Scholar]
  45. Zanchi D, Depoorter A, Egloff L, et al. The impact of gut hormones on the neural circuit of appetite and satiety: a systematic review. Neurosci Biobehav Rev 2017 ; 80 : 457–75. [CrossRef] [PubMed] [Google Scholar]
  46. Burrows K, McNaughton BA, Figueroa-Hall LK, et al. Elevated serum leptin is associated with attenuated reward anticipation in major depressive disorder independent of peripheral C-reactive protein levels. Sci Rep 2023 ; 13 : 11313. [CrossRef] [PubMed] [Google Scholar]
  47. Refisch A, Sen ZD, Klassert TE, et al. Microbiome and immuno-metabolic dysregulation in patients with major depressive disorder with atypical clinical presentation. Neuropharmacology 2023 ; 235 : 109568. [CrossRef] [PubMed] [Google Scholar]
  48. Sansonetti PJ, Doré J. Le microbiome humain à l’épreuve de l’anthropocène : de la corrélation à la causalité et à l’intervention. Med Sci (Paris) 2024 ; 40 : 757–65. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  49. Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019 ; 18 : 53–66. [CrossRef] [PubMed] [Google Scholar]
  50. Morris G, Puri BK, Carvalho A, et al. Induced ketosis as a treatment for neuroprogressive disorders: food for thought? Int J Neuropsychopharmacol 2020 ; 23 : 366–84. [CrossRef] [PubMed] [Google Scholar]
  51. Croatto G, Vancampfort D, Miola A, et al. The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: an umbrella review of the evidence from randomised controlled trials. Mol Psychiatry 2023 ; 28 : 369–90. [CrossRef] [PubMed] [Google Scholar]
  52. Firth J, Solmi M, Wootton RE, et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry 2020 ; 19 : 360–80. [CrossRef] [PubMed] [Google Scholar]
  53. Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 2020 ; 19 : 69–80. [CrossRef] [PubMed] [Google Scholar]
  54. Silva VA de, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016 ; 16 : 341. [CrossRef] [PubMed] [Google Scholar]
  55. Frajerman A, Morin V, Chaumette B, et al. Management of cardiovascular co-morbidities in young patients with early onset psychosis: state of the art and therapeutic perspectives. L’Encephale 2020 ; 46 : 390–8. [CrossRef] [Google Scholar]
  56. Trott M, Arnautovska U, Siskind D. GLP-1 receptor agonists and weight loss in schizophrenia — past, present, and future. Curr Opin Psychiatry 2024 ; 37 : 363–9. [CrossRef] [PubMed] [Google Scholar]
  57. Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry 2018 ; 23 : 335–43. [CrossRef] [PubMed] [Google Scholar]
  58. Poletti S, Zanardi R, Mandelli A, et al. Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: safety, efficacy, and immunological biomarkers. Brain Behav Immun 2024 ; 118 : 52–68. [CrossRef] [PubMed] [Google Scholar]
  59. Sousa CNS de, Silva Leite CMG da, Silva Medeiros I da, et al. Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review. Metab Brain Dis 2019 ; 34 : 39–52. [CrossRef] [PubMed] [Google Scholar]
  60. Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 2015 ; 55 : 294–321. [CrossRef] [PubMed] [Google Scholar]
  61. Scaini G, Rezin GT, Carvalho AF, et al. Mitochondrial dysfunction in bipolar disorder: evidence, pathophysiology and translational implications. Neurosci Biobehav Rev 2016 ; 68 : 694–713. [CrossRef] [PubMed] [Google Scholar]
  62. Bourre JM. Acides gras ω-3 et troubles psychiatriques. Med Sci (Paris) 2005 ; 21 : 216–21. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.